Bank of New York Mellon’s Evolent Health EVH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.87M | Buy |
344,628
+16,092
| +5% | +$61.7K | ﹤0.01% | 2989 |
|
|
2026
Q1 | $749K | Sell |
328,536
-18,640
| -5% | -$59.1K | ﹤0.01% | 3389 |
|
|
2025
Q4 | $1.39M | Sell |
347,176
-1,050,094
| -75% | -$5.84M | ﹤0.01% | 3056 |
|
|
2025
Q3 | $11.8M | Buy |
1,397,270
+234,473
| +20% | +$2.28M | ﹤0.01% | 1840 |
|
|
2025
Q2 | $13.1M | Sell |
1,162,797
-2,866
| -0.2% | -$26.3K | ﹤0.01% | 1741 |
|
|
2025
Q1 | $11M | Sell |
1,165,663
-269,937
| -19% | -$2.73M | ﹤0.01% | 1804 |
|
|
2024
Q4 | $16.2M | Sell |
1,435,600
-462,799
| -24% | -$8.13M | ﹤0.01% | 1686 |
|
|
2024
Q3 | $53.7M | Sell |
1,898,399
-149,942
| -7% | -$3.86M | 0.01% | 981 |
|
|
2024
Q2 | $39.2M | Buy |
2,048,341
+406,837
| +25% | +$10.4M | 0.01% | 1182 |
|
|
2024
Q1 | $53.8M | Sell |
1,641,504
-15,477
| -0.9% | -$494K | 0.01% | 987 |
|
|
2023
Q4 | $54.7M | Buy |
1,656,981
+1,372
| +0.1% | +$38.8K | 0.01% | 985 |
|
|
2023
Q3 | $45.1M | Buy |
1,655,609
+133,038
| +9% | +$3.7M | 0.01% | 1049 |
|
|
2023
Q2 | $46.1M | Sell |
1,522,571
-55,074
| -3% | -$1.78M | 0.01% | 1056 |
|
|
2023
Q1 | $51.2M | Buy |
1,577,645
+35,049
| +2% | +$1.11M | 0.01% | 1001 |
|
|
2022
Q4 | $43.3M | Sell |
1,542,596
-119,569
| -7% | -$3.43M | 0.01% | 1086 |
|
|
2022
Q3 | $59.7M | Sell |
1,662,165
-30,444
| -2% | -$1.07M | 0.01% | 844 |
|
|
2022
Q2 | $52M | Sell |
1,692,609
-188,084
| -10% | -$5.48M | 0.01% | 953 |
|
|
2022
Q1 | $60.7M | Sell |
1,880,693
-24,945
| -1% | -$653K | 0.01% | 975 |
|
|
2021
Q4 | $52.7M | Sell |
1,905,638
-72,352
| -4% | -$2.08M | 0.01% | 1116 |
|
|
2021
Q3 | $61.3M | Sell |
1,977,990
-20,716
| -1% | -$497K | 0.01% | 1006 |
|
|
2021
Q2 | $42.2M | Buy |
1,998,706
+78,583
| +4% | +$1.57M | 0.01% | 1259 |
|
|
2021
Q1 | $38.8M | Sell |
1,920,123
-92,429
| -5% | -$1.76M | 0.01% | 1282 |
|
|
2020
Q4 | $32.3M | Buy |
2,012,552
+151,691
| +8% | +$2M | 0.01% | 1328 |
|
|
2020
Q3 | $23.1M | Sell |
1,860,861
-39,415
| -2% | -$463K | 0.01% | 1385 |
|
|
2020
Q2 | $13.5M | Sell |
1,900,276
-74,309
| -4% | -$498K | ﹤0.01% | 1661 |
|
|
2020
Q1 | $10.7M | Buy |
1,974,585
+364,848
| +23% | +$3.26M | ﹤0.01% | 1664 |
|
|
2019
Q4 | $14.6M | Buy |
1,609,737
+964,723
| +150% | +$7.84M | ﹤0.01% | 1755 |
|
|
2019
Q3 | $4.64M | Sell |
645,014
-17,012
| -3% | -$122K | ﹤0.01% | 2318 |
|
|
2019
Q2 | $5.26M | Sell |
662,026
-2,860,378
| -81% | -$33.9M | ﹤0.01% | 2304 |
|
|
2019
Q1 | $44.3M | Sell |
3,522,404
-1,860,775
| -35% | -$29.5M | 0.01% | 1031 |
|
|
2018
Q4 | $107M | Sell |
5,383,179
-129,638
| -2% | -$3M | 0.03% | 486 |
|
|
2018
Q3 | $157M | Sell |
5,512,817
-63,392
| -1% | -$1.51M | 0.04% | 428 |
|
|
2018
Q2 | $117M | Sell |
5,576,209
-124,962
| -2% | -$2.37M | 0.03% | 525 |
|
|
2018
Q1 | $81.2M | Buy |
5,701,171
+2,261,550
| +66% | +$32.4M | 0.02% | 707 |
|
|
2017
Q4 | $42.3M | Buy |
3,439,621
+2,874,211
| +508% | +$40.5M | 0.01% | 1109 |
|
|
2017
Q3 | $10.1M | Buy |
565,410
+344,113
| +155% | +$7.09M | ﹤0.01% | 1990 |
|
|
2017
Q2 | $5.61M | Buy |
221,297
+85,406
| +63% | +$2.05M | ﹤0.01% | 2274 |
|
|
2017
Q1 | $3.03M | Sell |
135,891
-27,994
| -17% | -$537K | ﹤0.01% | 2601 |
|
|
2016
Q4 | $2.43M | Sell |
163,885
-145,701
| -47% | -$2.87M | ﹤0.01% | 2737 |
|
|
2016
Q3 | $7.62M | Sell |
309,586
-32,220
| -9% | -$753K | ﹤0.01% | 2001 |
|
|
2016
Q2 | $6.56M | Buy |
341,806
+42,414
| +14% | +$582K | ﹤0.01% | 2071 |
|
|
2016
Q1 | $3.16M | Buy |
299,392
+29,505
| +11% | +$305K | ﹤0.01% | 2411 |
|
|
2015
Q4 | $3.27M | Buy |
269,887
+216,200
| +403% | +$3.19M | ﹤0.01% | 2426 |
|
|
2015
Q3 | $857K | Buy |
53,687
+28,837
| +116% | +$563K | ﹤0.01% | 3277 |
|
|
2015
Q2 | $485K | Buy |
+24,850
| New | +$463K | ﹤0.01% | 3647 |
|
Other funds holding EVH
N
RPA
GCP
TC
Bank of New York Mellon's EVH Position: Q2 2026 in Review
Bank of New York Mellon increased its Evolent Health (EVH) stake by 4.9% in Q2 2026, buying an estimated $61.7K and bringing the position to 344,628 shares worth $1.87M. The position accounts for ﹤0.01% of the portfolio, ranked #2989.
Bank of New York Mellon first reported a position in EVH in Q2 2015 and has held it in 45 quarters since. The position peaked at $157M in Q3 2018. 88 funds tracked by Wall St. Rank hold EVH as of Q2 2026.
- Bank of New York Mellon held 344,628 shares of Evolent Health worth $1.87M as of Q2 2026.
- Bank of New York Mellon bought 16,092 Evolent Health shares in Q2 2026, an estimated $61.7K.
- Evolent Health made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2989 holding.
- Bank of New York Mellon first reported a position in Evolent Health in Q2 2015 and has held it in 45 quarters since.
- Bank of New York Mellon's Evolent Health position peaked at $157M in Q3 2018.
- 88 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.